Get the Stockscreener App
0.0158
75.56%
0.0068
Nls Pharmaceutics Ag stock is traded at $0.0158, with a volume of 1,320.
It is up +75.56% in the last 24 hours and up +8.22% over the past month.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
See More
Previous Close:
$0.009
Open:
$0.0157
24h Volume:
1,320
Relative Volume:
0.08
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.63%
1M Performance:
+8.22%
6M Performance:
-37.05%
1Y Performance:
+0.00%
1-Day Range:
$0.015
$0.0158
1-Week Range:
$0.009
$0.0158
52-Week Range:
$0.005
$0.1001
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Name
Nls Pharmaceutics Ag
Sector
Industry
Phone
41 44 512 21 50
Address
The Circle 6, Zurich
Compare NLSPW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NLSPW | 0.0158 | 0 | 0 | 0 | 0 | 0.00 |
| VRTX | 447.96 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.12 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.31 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.70 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Nls Pharmaceutics Ag Stock (NLSPW) Latest News
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com UK
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - Seeking Alpha
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - AccessWire
NLS Pharmaceutics Merges with Kadimastem for Strategic Growth - TipRanks
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com Nigeria
NLSP stock touches 52-week low at $4 amid sharp annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
NLS Pharmaceutics announces expected compliance with Nasdaq listing rules - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - AccessWire
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Outlines Capital and Share Strategy - TipRanks
NLS Pharmaceutics announces 1-for-40 reverse share split - TipRanks
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
BREAKING: NPA to ballot pharmacists on working to rule - The Pharmacist
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications - Yahoo Finance
Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Primecap Management Co. CA - MarketBeat
National Beverage: Growth Fizzing Out With Questionable Earnings Quality - Seeking Alpha
London NHS trust paid out more than £1.3m in mental health claims in 5years - Time 107.5
North East London NHS trust pays out £1.3m in mental health negligence cases - Waltham Forest Echo
Keeping an Eye on Newell Brands Inc (NWL) After Insider Trading Activity - Knox Daily
GSK Velu’s Neuberg Diagnostics in talks with 360One, M&G Investments for $100 mn pre-IPO fundraise - Moneycontrol
Newell Brands Inc. (NASDAQ:NWL) Shares Bought by Arizona State Retirement System - Defense World
RSV medication among new Pharmac funding options - RNZ
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex
How To Buy NLS Pharmaceutics AG Stock Online in August 2024 - Traders Union
NLS Pharmaceutics (NASDAQ:NLSP) Trading 4.3% Higher - Defense World
NLS Pharmaceutics Gains PwC’s Endorsement - TipRanks
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump - MSN
Nls Pharmaceutics Ag Stock (NLSPW) Financials Data
There is no financial data for Nls Pharmaceutics Ag (NLSPW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Cap:
|
Volume (24h):